This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siragy, H. M. Articles by Margolius, H. S. Search for Related Content PubMed PubMed Citation Articles by Siragy, H. M. Articles by Margolius, H. S.

(Hypertension. 1997;29:757-762.)
© 1997 American Heart Association, Inc.

Articles

Bradykinin B₂ Receptor Modulates Renal Prostaglandin E₂ and Nitric Oxide

Helmy M. Siragy; Ayad A. Jaffa; Harry S. Margolius

the Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, and the Departments of Pharmacology and Medicine, Medical University of South Carolina and Ralph A. Johnson VA Medical Center, Charleston.

Correspondence to Helmy M. Siragy, MD, Department of Medicine, Box 482, University of Virginia Health Sciences Center, Charlottesville, VA 22908.

Bradykinin and lys-bradykinin generated intrarenally appear to be important renal paracrine hormones. However, the renal effects of endogenously generated bradykinin are still not clearly defined. In this study, we measured acute changes in renal excretory and hemodynamic functions and renal cortical interstitial fluid levels of bradykinin, prostaglandin E₂, and cGMP in response to an acute intrarenal arterial infusion of the bradykinin B₂ receptor antagonist Hoe 140 (icatibant), cyclooxygenase inhibitor indomethacin, or nitric oxide synthase inhibitor N^G-monomethyl-L-arginine (L-NMMA) given individually or combined in uninephrectomized, conscious dogs (n=10) in low sodium balance. Icatibant caused a significant decrease in urine flow, urinary sodium excretion, and renal plasma flow rate (each P<.001). Glomerular filtration rate did not change during icatibant administration. Icatibant produced an unexpected large increase in renal interstitial fluid bradykinin (P<.0001) while decreasing renal interstitial fluid prostaglandin E₂ and cGMP (each P<.001). Both indomethacin and L-NMMA when given individually caused significant antidiuresis and antinatriuresis and decreased renal blood flow (each P<.001). Glomerular filtration rate decreased during L-NMMA administration (P<.001) and did not change during indomethacin administration. Combined administration of icatibant and indomethacin or L-NMMA caused significant decreases in renal excretory and hemodynamic functions, which were not different from changes observed with icatibant alone. The failure of icatibant to change renal function after inhibition of cyclooxygenase and nitric oxide synthase activity suggests that the effects of kinin B₂ receptor are mediated by intrarenal prostaglandin E₂ and nitric oxide generation. The increase in renal interstitial fluid bradykinin during icatibant requires further study of possible alterations in kinin synthesis, degradation, or clearance as a result of B₂ receptor blockade.

Key Words: bradykinin • interstitium • sodium • kidney • microdialysis • cyclic GMP • prostaglandin E₂

This article has been cited by other articles:

				B.#3.;e. B\#261;dzy\#324;ska and J. Sadowski Differential action of bradykinin on intrarenal regional perfusion in the rat: waning effect in the cortex and major impact in the medulla J. Physiol., August 1, 2009; 587(15): 3943 - 3953. [Abstract] [Full Text] [PDF]

				Y. Oishi, M. Masuda, T. Yasutsune, N. Boku, S. Tokunaga, S. Morita, and H. Yasui Impaired Endothelial Function of the Umbilical Artery After Fetal Cardiac Bypass Ann. Thorac. Surg., December 1, 2004; 78(6): 1999 - 2003. [Abstract] [Full Text] [PDF]

				Y. Tan, F. N. Hutchison, and A. A. Jaffa Mechanisms of angiotensin II-induced expression of B2 kinin receptors Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H926 - H932. [Abstract] [Full Text] [PDF]

				P. M. Abadir, R. M. Carey, and H. M. Siragy Angiotensin AT2 Receptors Directly Stimulate Renal Nitric Oxide in Bradykinin B2-Receptor-Null Mice Hypertension, October 1, 2003; 42(4): 600 - 604. [Abstract] [Full Text] [PDF]

				A. A. Jaffa, R. Durazo-Arvizu, D. Zheng, D. T. Lackland, S. Srikanth, W. T. Garvey, and A. H. Schmaier Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1215 - 1221. [Abstract] [Full Text] [PDF]

				B. Badzynska, M. Grzelec-Mojzesowicz, and J. Sadowski Prostaglandins but not nitric oxide protect renal medullary perfusion in anaesthetised rats receiving angiotensin II J. Physiol., May 1, 2003; 548(3): 875 - 880. [Abstract] [Full Text] [PDF]

				D. L. Kellogg Jr., Y. Liu, K. McAllister, C. Friel, and P. E. Pergola Bradykinin does not mediate cutaneous active vasodilation during heat stress in humans J Appl Physiol, October 1, 2002; 93(4): 1215 - 1221. [Abstract] [Full Text] [PDF]

				H. M. Siragy, M. de Gasparo, M. El-Kersh, and R. M. Carey Angiotensin-Converting Enzyme Inhibition Potentiates Angiotensin II Type 1 Receptor Effects on Renal Bradykinin and cGMP Hypertension, August 1, 2001; 38(2): 183 - 186. [Abstract] [Full Text] [PDF]

				C. D. Douillet, V. Velarde, J. T. Christopher, R. K. Mayfield, M. E. Trojanowska, and A. A. Jaffa Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-beta and MAPK Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2829 - H2837. [Abstract] [Full Text] [PDF]

				E. L. Greene, V. Velarde, and A. A. Jaffa Role of Reactive Oxygen Species in Bradykinin-Induced Mitogen-Activated Protein Kinase and c-fos Induction in Vascular Cells Hypertension, April 1, 2000; 35(4): 942 - 947. [Abstract] [Full Text] [PDF]

				J. Tornel, M. I. Madrid, M. Garcia-Salom, K. J. Wirth, and F. J. Fenoy Role of Kinins in the Control of Renal Papillary Blood Flow, Pressure Natriuresis, and Arterial Pressure Circ. Res., March 17, 2000; 86(5): 589 - 595. [Abstract] [Full Text] [PDF]

				D. Wang, H. Yoshida, Q. Song, L. Chao, and J. Chao Enhanced renal function in bradykinin B2 receptor transgenic mice Am J Physiol Renal Physiol, March 1, 2000; 278(3): F484 - F491. [Abstract] [Full Text] [PDF]

				R. M. Carey, Z.-Q. Wang, and H. M. Siragy Role of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure and Renal Function Hypertension, January 1, 2000; 35(1): 155 - 163. [Abstract] [Full Text] [PDF]

				P. S. Naidu, V. Velarde, C. S. Kappler, R. C. Young, R. K. Mayfield, and A. A. Jaffa Calcium-calmodulin mediates bradykinin-induced MAPK phosphorylation and c-fos induction in vascular cells Am J Physiol Heart Circ Physiol, September 1, 1999; 277(3): H1061 - H1068. [Abstract] [Full Text] [PDF]

				H. M. Siragy, T. Inagami, T. Ichiki, and R. M. Carey Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor PNAS, May 25, 1999; 96(11): 6506 - 6510. [Abstract] [Full Text] [PDF]

				D. J. Campbell, A. Kladis, T. A. Briscoe, and J. Zhuo Type 2 Bradykinin-Receptor Antagonism Does Not Modify Kinin or Angiotensin Peptide Levels Hypertension, May 1, 1999; 33(5): 1233 - 1236. [Abstract] [Full Text] [PDF]

				H. M. Siragy and R. M. Carey Protective Role of the Angiotensin AT2 Receptor in a Renal Wrap Hypertension Model Hypertension, May 1, 1999; 33(5): 1237 - 1242. [Abstract] [Full Text] [PDF]

				H. Yu, O. A. Carretero, L. A. Juncos, and J. L. Garvin Biphasic Effect of Bradykinin on Rabbit Afferent Arterioles Hypertension, August 1, 1998; 32(2): 287 - 292. [Abstract] [Full Text] [PDF]

				A. A. Jaffa, B. S. Miller, S. A. Rosenzweig, P. S. Naidu, V. Velarde, and R. K. Mayfield Bradykinin induces tubulin phosphorylation and nuclear translocation of MAP kinase in mesangial cells Am J Physiol Renal Physiol, December 1, 1997; 273(6): F916 - F924. [Abstract] [Full Text] [PDF]